Skip to content

Study · Animal study (in vivo) · rat · 2006

1 result

[Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten].

Vakhitova IuV, Sadovnikov SV, Iamidanov RS, Seredenin SB

Genetika1 Jul 2006Cited by 1 (Europe PMC)

PMID16915929 (opens in a new tab)PepBankPUB-16915929

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rat hypothalamus, Ladasten increased cytosine demethylation frequency at some transcription-factor binding sites or neighboring motifs compared with control rats.

    In plain wordsIn rats, Ladasten increased removal of methyl groups at some tyrosine hydroxylase regulatory sites compared with control rats.

    Peptide
    Bromantane
    Outcome
    IncreaseCytosine demethylation frequency
    Study

    ratn: not reported in source

    Rat hypothalamus
    Comparator
    Control rats
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · single exposureAs given in this study (rat).

    Source sentences

    Summary
    Ladasten was shown to increase frequency of cytosine demethylation in binding sites of some transcription factors or in neighboring motifs.
    1 context sentence
    Summary · context
    In the present study, we employed the bisulfate sequencing technique to detect changes of GpG islands methylation status in the TH gene 5'-flanking region (-650 + 84) in hypothalamus cells of control and experimental rats after a single exposure to Ladasten.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.